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Background
Tyrosine kinase inhibitors (TKIs) form an important class 
of drugs used in molecularly targeted therapy, and they 
have been widely used in the management of various 
advanced malignancies [1–3]. The therapeutic efficacy 
of TKIs is achieved mainly by the inhibition of the intra-
cellular kinase domains [1, 4]. Sorafenib (Nexavar; Bayer 
Pharma AG, Leverkusen, Germany) is a small-molecule 
TKI that inhibits several tyrosine kinases, including vas-
cular endothelial growth factor (VEGF) receptor, platelet-
derived growth factor (PDGF) receptor, and the Raf kinases 
[1–3]. Hence, sorafenib has been used to treat advanced 
hepatocellular carcinoma (HCC), renal cell carcinoma 
(RCC), and thyroid cancer.
Recently, as the patients’ prognosis with molecularly 
targeted therapy has been improving, a growing number 
of unexpected effects are being reported. In addition to 
the common adverse effects of sorafenib such as diarrhea, 
hand-foot skin reaction (HFSR), and pancreatitis [2–4], 
some effects that are detected with imaging have also been 
reported. Thyroid atrophy is one such effect [5]. Skeletal 
atrophy has also been demonstrated in patients who had 
received sorafenib for 12 months [6], and several articles 
have recently reported sorafenib-associated pancreatic 
atrophy [7–11]. Sunitinib (Sutent; Pfizer, NY, United States), 
another type of TKI that inhibits the VEGF receptor, has 
been reported to cause prostate volume reduction (PVR) 
and thereby reduce obstructive urinary symptoms [12]. It 
shares similar molecularly targeted effects as sorafenib, 
and demonstrates some of the same effects, such as thy-
roid and pancreatic atrophy [11, 13, 14]. However, there 
has been no research on whether sorafenib induces PVR, 
and the correlation between the sorafenib-associated 
PVR and the other clinical indicators remains unclear. 
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Sorafenib-induced Prostate Volume Reduction, a New 
Adverse Effect Detected by Imaging: A Pilot Study
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Kuniaki Fukuda‡, Kazuhiro Takahashi§, Toshitaka Ishiguro*, Takahiro Hosokawa‖ and 
Manabu Minami*
Background: Sorafenib has been used in the treatment of advanced hepatocellular carcinoma (HCC) and 
renal cell carcinoma (RCC). Sorafenib-associated organ reduction have been reported on imaging, such as 
thyroid, pancreas and muscle, but there has been no research on prostate volume reduction (PVR).
Methods: We retrospectively analyzed 26 patients (twenty with HCC and six patients with RCC) who 
underwent sorafenib therapy for 31 to 1225 days (median, 100 days). PVR was estimated by two inde-
pendent readers using CT volumetry.
Results: The sum of all prostate volumes measured by reader 1 was 24.2 ± 13.8 cm3 on the baseline CT 
and 20.4 ± 10.6 cm3 on the follow-up CT (p < 0.001), and that measured by reader 2 was 22.3 ± 13.9 
cm3 on the baseline CT and 19.2 ± 10.6 cm3 on the follow-up CT (p < 0.001). The concordance correla-
tion coefficient for the prostate volume measured by the two readers was 0.95 on the baseline CT scans 
and 0.94 on the follow-up CT scans. Sorafenib-associated PVR demonstrated slight dependence to the 
exposure time (r = –0.23). One patient with benign prostatic hyperplasia (BPH) showed PVR (from 80.4 
to 61.5 cm3 [reader 1]; 83.4 to 61.6 cm3 [reader 2]) after sorafenib administration. Sorafenib-associated 
PVR occurred in patients both with and without underlying liver dysfunction with relative prostate volume 
changes of 86.7 ± 12.0% and 85.0 ± 9.0%, respectively.
Conclusion: Our study demonstrated significant PVR with sorafenib treatment in patients regardless of 
the presence of BPH and underlying liver dysfunction.
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Hence, the purpose of our study was to clarify the effect 
of sorafenib on prostate volume using a cohort of patients 
with either HCC or RCC, and to analyze the correlation 
between PVR and the degree of sorafenib exposure, and 
the degree of adverse events. Furthermore, we also inves-
tigated the correlation between the sorafenib-associated 
PVR and underlying liver dysfunctions, and benign pros-
tatic hyperplasia (BPH).
Methods
This retrospective study was approved by our Institutional 
Review Board (H29-110). The requirement for written 
informed consent was waived by the Institutional Review 
Board due to the retrospective nature of the study.
Study population and data acquisition
Among the male patients with HCC or RCC who underwent 
computed tomography (CT) scans between April 2008 and 
March 2017, those who were treated with sorafenib were 
located. The inclusion criteria for the study were as fol-
lows: (i) sorafenib therapy had been continued for at least 
one month; (ii) a baseline CT scan was obtained before ini-
tiating the therapy; and (iii) at least one follow-up CT scan 
was obtained during sorafenib treatment. The following 
patients were excluded from the patient group: (i) those 
who were previously diagnosed with prostate malignancy; 
and (ii) those who had received hormonal replacement 
therapy. We identified 26 patients eligible to participate 
in this study: twenty with HCC and six with RCC.
Clinical data regarding age, underlying liver disease, 
underlying BPH, the number of days from the begin-
ning of treatment to the follow-up CT scan, the cumula-
tive dose of sorafenib received from the beginning of the 
treatment to the sequential follow-up CT scans, and the 
grade of the adverse effects according to the National 
Cancer Institute Common Toxicity Criteria for Adverse 
Events version 4.0 were retrospectively collected. Patients 
were assumed to have underlying BPH if they had been 
clinically diagnosed with BPH before initiating sorafenib 
therapy. Patients who had been clinically diagnosed with 
cirrhosis or other chronic liver dysfunction before initiat-
ing sorafenib therapy were considered to have underly-
ing liver disease. The degree of liver fibrosis in patients 
with liver dysfunction was assessed by the FIB-4 score, 
which is a noninvasive estimate of liver fibrosis defined as 
9(AST (IU/L) × age (year))/(platelet count (10 /L () /× ) ) ALT IU L  [15–17]. Sorafenib 
was orally administered at 200 mg once daily, 400 mg 
once daily, 200 mg once, 400 mg once daily, or 400 mg 
twice daily doses. Dose reduction or interruption of the 
therapy had been performed according to the grade of the 
adverse effect. In case of definitive disease progression, 
sorafenib therapy was permanently continued.
CT technique and imaging analysis
CT examinations were performed using multi-row detec-
tor CT scanners with 256, 64, or 16 detector rows (Bril-
liance iCT 256, Brilliance 64, Brilliance 16, or M × 8000 
IDT 16, Philips Medical Systems, Best, the Netherlands). 
The collimation width of each detector was 0.625 mm 
in the iCT256 and Brilliance 64 scanners, and 1.5 mm 
in the Brilliance 16 and M × 8000 IDT 16 scanners. In 
all patients, CT scans were performed in the supine posi-
tion during inspiration breath-hold. The beam pitch was 
0.45 to 0.90. Patients with no contraindication for the 
intravenous injection (IV) of iodinated contrast agents 
had undergone contrast-enhanced abdominal CT scans. 
In our study, the contrast-enhanced CT images in the 
portal venous phase were included for analysis. Patients 
with renal insufficiency in whom IV contrast agents were 
contraindicated underwent plain CT scans. The images 
without contrast enhancement in these patients were 
also included.
In patients with HCC, the portal venous phase images 
were automatically initiated 50 seconds after the atten-
uation of the abdominal aortic blood reached 150 
Hounsfields units. In patients with RCC, the portal venous 
phase images were acquired 80 seconds after the con-
trast agent was injected. All 20 patients with HCC and 
five out of six patients with RCC were administered iodi-
nated contrast agents IV for their baseline CT studies. In 
patients with HCC, 31 follow-up CTs were performed and 
in patients with RCC 17 follow-up CTs were performed. Of 
these, 29 and 11 follow-up CTs, respectively, were in the 
portal venous phase. The remaining CT scans were per-
formed without using an IV contrast agent.
The Centricity Universal Viewer 6.0 sp7 and Advanced 
Visualization 3.2 (GE Healthcare, Chicago, IL, USA) were 
used for image analysis. The volume of the prostate in each 
CT scan was measured using the “Auto Contour” function, 
which helped the interpreter to easily perform automated 
volumetric measurements by area summation. All the 2 
mm axial thin slice images of the selected CT scans were 
anonymized and sent to the workstation. The margins of 
the prostate were manually outlined by two independent 
readers (HT, and SM, radiologists with 7 and 4 years of 
experience, respectively) (Figure 1A, B). The surrounding 
structures such as vessels and seminal vesicles were care-
fully excluded from the region of interest (ROI).
Statistical analysis
The prostate volumes in the baseline and in the final 
follow-up CT scans that were measured by the two inde-
pendent readers were assessed by the Wilcoxon signed 
rank test. The inter-observer agreement for the prostate 
volume measurements from the baseline and follow-up 
CT scans were assessed using the concordance correla-
tion coefficient. The agreement between the two readers 
was visually demonstrated by using Bland-Altman plots 
with 95% limits. The Wilcoxon rank sum test was used to 
assess the difference of the prostate volume in the base-
line CT and the change in the prostate volume from the 
baseline CT to the final follow-up CT between patients 
with liver dysfunction and those without liver dysfunc-
tion. The associations between the continuous variables 
were investigated using the Pearson’s correlation coef-
ficient. In the latter two statistical analyses, we averaged 
the value of prostate volume measured by the two read-
ers. P values of the respective statistical tests were calcu-
lated. All data were analyzed with the statistical software 
R (version 3.3.2).
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Results
The patient characteristics are summarized in Table 1. Our 
study included 26 patients for analysis, of whom twenty 
had HCC and six had RCC. One patient with HCC had been 
clinically diagnosed with BPH for which he had not under-
gone any treatment. All the patients with HCC had under-
lying liver cirrhosis, whereas one of the six patients with 
RCC had alcoholic hepatitis. Five of the patients with RCC 
did not have any liver disease.
The therapy duration ranged from 31 to 1225 days 
(median, 100 days) and the cumulative dose of sorafenib 
ranged from 11.2 to 364 g (median, 47.4 g). The baseline CT 
scans were performed at a mean of 25.9 days (range 0–148 
days) before initiating sorafenib treatment. The prostate 
volumes before and after sorafenib treatment as measured 
by the two independent readers are summarized in Table 
2 and plotted in Figure 2. The summed prostate volumes 
of the whole cohort was 24.2 ± 13.8 cm3 on the baseline CT, 
and 20.4 ± 10.6 cm3 on the final follow-up CT (p < 0.001) 
when measured by reader 1; and it was 22.3 ± 13.9 cm3 on 
the baseline CT and 19.2 ± 10.6 cm3 on the final follow-
up CT (p < 0.001) when measured by reader 2. Significant 
prostate volume reductions after sorafenib administration 
were observed by both the readers across the entire cohort, 
the patients with HCC, and those with RCC. 
The concordance correlation coefficient for the pros-
tate volumes measured by the two readers was 0.95 (95% 
confidence interval [CI]: 0.90, 0.97) on the baseline CT 
scans and 0.94 (95% CI: 0.89, 0.97) on all the follow-up 
CT scans. The agreement between the two readers was 
assessed by the Bland-Altmann plots (Figure 3A, B). The 
mean difference was 1.9 for the baseline CT scans and 1.4 
for all the follow-up CT scans. The 95% limits of agree-
ment between the two readers on the Bland-Altman plots 
were –5.7 to 9.5 for the baseline CT scans and –4.5 to 7.4 
for all the follow-up CT scans.
The relative prostate volume changes on the final fol-
low-up CT scans from the baseline CT scans, obtained by 
averaging the values measured by the two observers, were 
86.4 ± 11.4% (65.1 to 113.1%) in all patients, 85.3 ± 12.2% 
(65.1 to 113.1%) in HCC patients, and 86.6 ± 9.0% (74.4 
to 95.5%) in RCC patients. Of the 26 patients, 23 showed 
PVR when treated with sorafenib. Three patients showed 
increased prostate volume of 113.1%, 101.0%, and 103.2%, 
respectively. The therapy durations and cumulative doses 
of sorafenib in the three patients were 131 days (52.8 g), 
172 days (39.2 g), and 66 days (29.8 g), respectively.
Each patient’s relative prostate volume change from 
the baseline CT to the follow-up CT scans was plotted as 
a function of the follow-up interval (Figure 4A) and as a 
function of the cumulative dose of sorafenib (Figure 4B). 
Sorafenib-associated prostate volume change demon-
strated dependence on the exposure time (r = –0.23), but 
not on the cumulative dose (r = –0.18). There was no 
Figure 1: The measurement of the prostate volume using auto-contour measurement.
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correlation between the relative volume change of the 
prostate and the degree of diarrhea (r = –0.12), or the 
degree of HFSR (r = 0.13). 
The prostate volumes of patients with underlying 
liver dysfunction were compared with those without 
underlying liver dysfunction. The mean prostate volume 
on the baseline CT scans was 22.4 ± 14.7 cm3 in patients 
with liver dysfunction (n = 21; twenty patients with 
HCC patients, and one with RCC), and 26.9 ± 9.1 cm3 in 
patients without liver dysfunction (n = 5; all patients had 
Table 1: Patient characteristics.
All patients HCC patients RCC patients
Total number 26 20 6
Benign prostatic hyperplasia (BPH) 1 1 0
Liver dysfunction† 21 20 1
Liver cirrhosis 20 20 0
Viral hepatitis – HBV 4 (19) 4 (20) 0 (0)
Viral hepatitis – HCV 10 (48) 10 (50) 0 (0)
Alcohol 3 (14) 3 (15) 0 (0)
Nonalcoholic steatohepatitis 3 (14) 3 (15) 0 (0)
Chronic liver dysfunction other 
than cirrhosis
1 (5) 0 (0) 1 (100)
Median age at sorafenib start, years‡ 71.0 (40–89) 70.0 (40–81) 73.5 (61–89)
Median exposure time to sorafenib, 
days‡
100 (31–1225) 90 (31–1225) 211 (46–674)
Median cumulative sorafenib dose, 
grams‡
47.4 (11.2–364) 46.0 (11.2–364) 50 (16.8–213)
Mean follow-up CT scans‡ 1.8 (1–7) 1.6 (1–3) 2.8 (1–7)
Diarrhea, grade†
0 15 (58) 10 (50) 5 (83)
1 5 (19) 5 (25) 0 (0)
2 4 (15) 3 (15) 1 (17)
3 2 (8) 2 (10) 0 (0)
HFSR, grade†
0 6 (23) 6 (30) 0 (0)
1 11 (42) 7 (35) 4 (67)
2 4 (15) 3 (15) 1 (17)
3 5 (19) 4 (20) 1 (17)
† Numbers in parenthesis are percentages.
‡ Numbers in parenthesis are ranges.
Table 2: Prostate volumes in baseline and final follow-up CT scans as assessed by two independent readers.
Reader 1 Reader 2
Prostate volume 
in the baseline 
CT scan (cm3)† 
Prostate volume 
in the final follow-
up CT scan (cm3)†
P 
value
Prostate volume 
in the baseline 
CT scan (cm3)† 
Prostate volume 
in the final follow-
up CT scan (cm3)†
P 
value
All patients 
(n = 26)
24.2 ± 13.8 
(10.1–80.4)
20.4 ± 10.6 
(9.9–61.5)
<0.001* 22.3 ± 13.9 
(10.5–83.7)
19.4 ± 10.6 
(8.4–61.6)
<0.001*
HCC patients 
(n = 20)
22.9 ± 14.8 
(10.1–80.4)
19.3 ± 11.2 
(9.9–61.5)
<0.001* 21.8 ± 15.5 
(10.5–83.7)
18.5 ± 11.2 
(8.4–61.6)
<0.001*
RCC patients 
(n = 6)
28.7 ± 9.4 
(17.2–41.2)
24.4 ± 7.9 
(12.1–34.9)
0.031* 24.0 ± 7.3 
(15.7–35.5)
21.9 ± 8.3 
(11.4–33.4)
0.031*
† Numbers in parenthesis are ranges.
* Statistically significant.
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RCC). The difference between the two groups showed no 
statistical significance (p = 0.178). The relative prostate 
volume changes from the baseline CT scans to the final 
follow-up CT scans were 86.7 ± 12.0% in patients with 
liver dysfunction and 85.0 ± 9.0% in patients without 
liver dysfunction (p = 0.753). The FIB-4 score in patients 
with liver dysfunction ranged from 1.5 to 13.6 (median: 
3.3). Sorafenib-associated prostate volume change dem-
onstrated dependence on the FIB-4 score (r = 0.26) in 
patients with liver dysfunction (Figure 4C). 
One patient with HCC also had BPH (patient 1). The 
prostate volume of this patient was 80.4 cm3 (reader 1), 
and 83.7 cm3 (reader 2) on the baseline CT, and 61.5 cm3 
(reader 1), and 61.6 cm3 (reader 2) on the final follow-up 
CT (Figure 4D, E). The duration of sorafenib therapy was 
31 days, and the cumulative dose of sorafenib was 11.2 
g. We also investigated from medical records the urinary 
symptoms of patients in the study cohort. One patient 
(Patient 2) with HCC had remarked that his urine output 
had improved after sorafenib therapy. His prostate volume 
was 24.0 cm3 (reader 1) and 23.0 cm3 (reader 2) on the 
baseline CT, and 15.7 cm3 (reader 1) and 19.2 cm3 (reader 
2) on the final follow-up CT. The duration of sorafenib 
therapy was 1225 days and the cumulative dose was 184 g.
Discussion
Our study investigated the prostate volume change after 
sorafenib treatment. Two independent readers measured 
the prostate volumes of 26 patients who underwent 
sorafenib therapy (twenty patients with HCC, and six with 
RCC). Statistically significant PVR was observed in the 
respective measurements performed by the two readers. 
The concordance correlation coefficient for the prostate 
volume calculated by the two readers was substantial on 
the baseline CT scans (0.95) and the moderate on the 
follow-up CT scans (0.94), suggesting that the interrater 
agreement was good.
Our study also revealed that sorafenib-associated 
prostate volume change tend to be dependent on the 
exposure time (r = –0.23). The PVR of Patient 1 was 
observed within a relatively short period of sorafenib 
exposure (the therapy duration was 31 days). However, 
three other patients showed increases in their prostate 
volumes within 180 days of therapy. With long-term 
sorafenib therapy, the effect of PVR was more certain 
(Figure 4A, B).
One patient (Patient 1) with HCC who had been clini-
cally diagnosed with BPH also showed PVR after sorafenib 
administration. He did not take any medication for BPH 
Figure 2: Plotted prostate volumes on the baseline and final follow-up CT as assessed by two readers.
Figure 3: (A) Bland-Altman plots of prostate volume as measured by the two readers on baseline CT scans. (B) Bland-
Altman plots of prostate volume as measured by two readers on the follow-up CT scans.
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Figure 4: (A) The prostate volume change with sorafenib treatment as a function of the exposure time. The correlation 
coefficient r was –0.23. (B) The prostate volume change with sorafenib treatment as a function of the cumulative 
dose. The correlation coefficient r was –0.18. (C) The prostate volume change with sorafenib treatment as a function 
of FIB-4 score. The analyzed subjects were patients with liver dysfunction (n = 21, twenty patients with HCC and 
one with RCC). The correlation coefficient r was 0.26. (D, E) The prostate volume change after sorafenib treatment 
in patient with HCC and prostate hyperplasia. The prostate volume reduction after sorafenib administration in this 
patient was 80.4 cm3 (reader 1) and 83.7 cm3 (reader 2) on the baseline CT, and was 61.5 cm3 (reader 1) and 61.6 cm3 
(reader 2) in the final follow-up CT. The therapy duration was 31 days; the cumulative dose was 11.2 g.
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during the observation period. His prostate volume 
reduced from 80.4 cm3 to 61.5 cm3 (reader 1), and from 
83.7 cm3 to 61.6 cm3 (reader 2) after sorafenib therapy 
(Figure 4D, 4E). On reviewing medical records, we found 
another patient (Patient 2) with HCC who remarked that 
his urine output had improved after sorafenib therapy. His 
prostate volume reduced from 24.0 cm3 to 15.7 cm3 (reader 
1), and from 23.0 cm3 to 19.2 cm3 (reader 2) after therapy. 
Hatano et al. demonstrated that RCC patients who had 
undergone sunitinib administration showed a significant 
PVR and an improvement in urinary symptoms at week 24 
[12]. Therefore, there is a possibility that sorafenib admin-
istration may also lead to the amelioration of the urinary 
symptoms by reducing the prostate volume.
It has been reported that BPH occurred in fewer cirrhotic 
patients when compared to the general population [18]. 
Frea et al. reported that the prevalence of BPH in patients 
with cirrhosis was 41% whereas that in controls was 71% 
[18]. Mesut et al. demonstrated that the mean prostate 
volume was 17.9 ± 6.8 cm3 in patients with cirrhosis (n 
= 60) whereas it was 27.6 ± 8.6 cm3 in controls (n = 20) 
[19]. These results could be partly explained by the fact 
that the prostatic epithelium responds to androgens, the 
level of which is reduced in patients with cirrhosis [18, 19]. 
This was consistent with the finding in our study that the 
prostate volume in the baseline CT was larger in patients 
without liver dysfunction (26.9 ± 9.1 cm3) when com-
pared to those with liver dysfunction (22.4 ± 14.7 cm3), 
although the difference between the two groups was 
not statistically significant (p = 0.178). Our study showed 
that although sorafenib-associated PVR occurred regard-
less of the presence of underlying liver dysfunction, it 
was slightly dependent on the FIB-4 score (r = 0.26). Our 
findings suggested that PVR with sorafenib therapy could 
occur even in patients with decreased androgenic activ-
ity due to liver dysfunction, but that the degree of PVR 
might be relatively small in patients with progressive liver 
fibrosis.
The molecular mechanism by which PVR occurs with 
sorafenib is considered to be different from that of exist-
ing drugs. For instance, Chiu et al. demonstrated that 
finasteride, a 5α-reductase inhibitor used in BPH, also 
causes PVR with an average reduction in prostate vol-
ume from 39.8 ± 21.1 mL to 33.6 ± 20.5 mL with finas-
teride treatment when evaluated by ultrasonography [20]. 
Finasteride-associated PVR is thought to be due to the 
anti-androgenic effect brought by the reduced formation 
of dihydrotestosterone from its precursor testosterone 
[21]. Whereas, sorafenib-associated PVR could be partly 
explained by the inhibition of the VEGF and PDGF recep-
tors, since previous reports have demonstrated that VEGF 
and PDGF stimulate the endothelial and epithelial cells 
in normal prostate glands [12, 22, 23]. Sorafenib has also 
been demonstrated to decrease the proliferation of pros-
tate cancer cells by inhibiting the androgen receptor and 
the Akt signaling pathway, thereby resulting in cell death 
[24]. It is possible that sorafenib induces this inhibitory 
function in normal prostate glands as well. The further 
investigation of these mechanisms of sorafenib that cause 
PVR could lead to further development of the treatment 
of BPH that is resistant to therapy.
Our retrospective pilot study had several limitations. 
First, some CT scans were taken without IV contrast 
enhancement due to renal dysfunction, and the timings of 
the portal venous images were different between patients 
with HCC and those with RCC. This could have caused slight 
differences in visualizing the boundaries of prostate and 
might have affected the volume estimated by the two read-
ers to some extent. This was unavoidable since we included 
RCC patients in the analysis, who were prone to develop 
renal dysfunction. Second, we did not analyze the corre-
lation between the PVR and the patients’ prognosis. This 
is because, we considered the prostate volume reduction 
to be a relatively early onset adverse effect and included 
patients who were administered sorafenib for shorter dura-
tions. Thus, any prognostic information obtained from our 
study cohort would have had little value. Third, due to the 
retrospective nature of the study, we could evaluate uri-
nary symptoms in the patients only by investigating their 
medical records. Further quantitative analysis, including 
IPSS score, urine flow measurement, and residual urine 
measurement, would be necessary to assess the correlation 
between sorafenib-associated PVR and urinary functions.
Conclusions
Our pilot study has made the novel demonstration of pros-
tate volume reduction with sorafenib therapy. Sorafenib-
associated prostate volume reduction could occur in patients 
regardless of the presence of liver dysfunction or BPH.
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